{"id":94495,"topic":"peptides","source":"观点网","title":"九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流 - 观点网","url":"https://www.guandian.cn/m/show/609212","url_hash":"6509ae03a2f7fabce433216f9bcb8d7ca9ae29ac","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiTkFVX3lxTFA1UXBLelY1aHJxQm1KT1ctd1dnX3p4ZmtTRERMc21DYnFPNGdzQTlsOHNGNzJYVDRBVjBTYjg2RHpiOV9kZ2hzUk9KQ3c1Zw?oc=5\" target=\"_blank\">九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">观点网</font>","content":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","image_url":null,"lang":"zh","published_at":"2026-09-30T13:33:52+00:00","fetched_at":"2026-10-02T05:15:13+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.guandian.cn/m/show/609212","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 177 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":177,"summary_length":177,"usable_text_length":177,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":177,"summary_length":177}},"news_item":{"id":94495,"canonical_url":"https://www.guandian.cn/m/show/609212","source_url":"https://www.guandian.cn/m/show/609212","title":"九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流 - 观点网","source_name":"观点网","author":null,"published_at":"2026-09-30T13:33:52+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiTkFVX3lxTFA1UXBLelY1aHJxQm1KT1ctd1dnX3p4ZmtTRERMc21DYnFPNGdzQTlsOHNGNzJYVDRBVjBTYjg2RHpiOV9kZ2hzUk9KQ3c1Zw?oc=5\" target=\"_blank\">九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">观点网</font>","full_text":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","excerpt":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 177 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/609212","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 177 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":177,"summary_length":177,"usable_text_length":177,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":177,"summary_length":177}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流 - 观点网","url":"https://www.guandian.cn/m/show/609212","summary":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","source":"观点网","date":"2026-09-30T13:33:52+00:00","content":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/609212","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 177 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 177 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":177,"summary_length":177,"usable_text_length":177,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":177,"summary_length":177}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/94495","export_markdown":"/api/items/94495/export?format=markdown","export_json":"/api/items/94495/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/609212"},"formats":{"full":{"id":94495,"title":"九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流 - 观点网","url":"https://www.guandian.cn/m/show/609212","source":"观点网","author":null,"published_at":"2026-09-30T13:33:52+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","full_text":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 177 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/609212","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 177 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":177,"summary_length":177,"usable_text_length":177,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":177,"summary_length":177}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 177 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":177,"summary_length":177,"usable_text_length":177,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":177,"summary_length":177}},"actions":{"read":"/item/94495","export_markdown":"/api/items/94495/export?format=markdown","export_json":"/api/items/94495/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/609212"}},"digest":{"id":94495,"title":"九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流 - 观点网","url":"https://www.guandian.cn/m/show/609212","source":"观点网","topic":"peptides","published_at":"2026-09-30T13:33:52+00:00","excerpt":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。 公告显示，本次补流金额占2021年可转债募资总额的36.48%。 截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。 该事项已经公司董事会审议通过，尚需提交股东会审议。","quality_bucket":"medium","quality_reason":"Medium confidence: short full text extraction produced 177 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流 - 观点网","subtitle":"观点网 · 2026-09-30","summary":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。 公告显示，本次补流金额占2021年可转债募资总额的36.48%。 截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。 该事项已经公司董事会审议通过，尚需提交股东会审议。","badges":["quality:medium"],"links":{"read":"/item/94495","original":"https://www.guandian.cn/m/show/609212","diagnose":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/609212"},"quality_warning":null},"export":{"title":"九典制药拟终止抗菌多肽新药研发项目 剩余募资9849.18万元补流 - 观点网","url":"https://www.guandian.cn/m/show/609212","summary":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","source":"观点网","date":"2026-09-30T13:33:52+00:00","content":"观点网讯：九典制药公告称，公司拟终止\"抗菌多肽新药研发项目\"，将该项目剩余募集资金9849.18万元永久补充流动资金，用于主营业务相关日常经营活动。\n公告显示，本次补流金额占2021年可转债募资总额的36.48%。\n截至2026年6月30日，该项目累计投入募集资金301.56万元，投入进度3.07%。\n该事项已经公司董事会审议通过，尚需提交股东会审议。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/609212","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 177 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 177 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":177,"summary_length":177,"usable_text_length":177,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":177,"summary_length":177}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}